News Release

Journal Article Cites AlbuVoid™ in Secretome Study of Human Induced Pluripotent Stem Cells (hiPSCs) Under Investigation For In Vitro Fertilization (IVF)

MONMOUTH JUNCTION, NJ, November 5, 2024 -- Biotech Support Group reports on a recent journal article using AlbuVoid™ for investigating the protein secretome from differentiated ovarian support cells (OSCs).

The citation is:

Paulsen, Bruna, et al. "Reproducible differentiation of pure ovarian support cells from clinical-grade hiPSCs as a novel infertility treatment." bioRxiv (2024): 2024-04. 

In vitro maturation (IVM) is an infertility treatment used during in vitro fertilization (IVF) procedures in which immature oocytes are matured outside the body. To overcome the historically low embryo formation rate associated with IVM, the authors have recently demonstrated that co-culture of human induced pluripotent stem cells (hiPSC)-derived ovarian support cells (OSCs) yielded higher rates of oocyte maturation and euploid embryo formation, by mimicking the complex ovarian environment in vitro. To translate this process into clinics, the investigators sourced and engineered a compliant female clinical-grade (CG) hiPSC line to derive OSCs with similar quality attributes and clinical outcomes to results previously demonstrated with a research hiPSC line. To gain insight into the potential mechanism of action of these cells during oocyte maturation beyond transcriptomics readouts, the investigators also performed secretome proteomics to investigate proteins that overexpressed in OSC after 24 hours in vitro in comparison with OSCs prior to culture (0 hour) from cells derived, from both CG-hiPSC and RUO-hiPSC.

For proteomic analysis, the article states, “The conditioned media were subjected to consecutive centrifugations (300g, 1,200g, and 3,000g) to remove cellular remnants, and then passed through albumin depletion columns (AVK-50, AlbuVoid Albumin Depletion Columns Biotech Support Group) to eliminate HSA-derived albumin.” In conclusion, this study describes generation and comparability of a clinical-grade starting material (CG-hiPSCs) to support development of a novel cellular additive for in vitro maturation of human oocytes (OSC-IVM), as well as manufacturing adaptations required to convert this technology into a clinical-grade product. OSC-IVM has been demonstrated to efficiently drive oocyte maturation, and once fully integrated into clinical practice, has the potential to substantially impact patients interested in egg freezing and in vitro fertilization. 

“Here is another reference that shows that AlbuVoid™ is very efficient for depleting albumin from cell secretomes, enriching the Albumin-depleted sub-proteome, and suitable for productive LC-MS proteomic analysis.”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: AlbuVoid™ at
https://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm

And AlbuVoid™ LC-MS On-Bead For Serum Proteomics, at

https://www.biotechsupportgroup.com/AlbuVoid-LC-MS-On-Bead-For-Serum-Proteomics-p/avb-ms.htm

For more information on our complete line of Albumin & IgG Removal, visit:

https://www.biotechsupportgroup.com/Albumin-Removal-s/307.htm

Keywords

Albumin Removal, Albumin Depletion, AlbuVoid™, Human Induced Pluripotent Stem Cells (hiPSCs), In vitro maturation (IVM), oocyte maturation

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

Contact:
Matthew Kuruc 732-274-2866

mkuruc@biotechsupportgroup.com